Incyte Corp
NASDAQ: INCY
$80.58
-$0.95 (-1.2%)
Closing Price on November 12, 2024
INCY Articles
After the announcement that its Phase 2 trial of Ruxolitinib would be stopped a few analysts took a deeper look at Incyte and realized that it might not be as bad as initially thought.
Published:
Last Updated:
Thursday's top analyst calls include Boeing, eBay, Facebook, Incyte, Kinder Morgan, PayPal, Qualcomm and U.S. Steel.
Published:
Last Updated:
Credit Suisse sees solid fundamentals, despite a harsh market landscape, for large-cap biotech firms. It initiated several top biotech stocks with an Outperform rating.
Published:
Last Updated:
Wednesday's top analyst calls include AMD, Amazon.com, Celgene, Comerica, Fortinet, Gilead Sciences, Lennar, Netflix, Voya and Wayfair.
Published:
Last Updated:
The top analyst calls for Wednesday, January 6, 2016, include Bluebird Bio, Check Point Software, Comcast, Eli Lilly, Hyatt Hotels, Lockheed Martin and Rite Aid.
Published:
Last Updated:
This week the Jefferies analysts are positive on companies that took a shot price-wise last week and may be offering an even better entry point for investors.
Published:
Last Updated:
These three top biotech names are very good bets for investors looking to add high-quality companies with less volatility and binary clinical data risk.
Published:
These four top large cap biotechs are very good bets for investors looking to add high-quality companies with less volatility and binary clinical data risk.
Published:
In a new and very comprehensive report, Jefferies starts coverage on biotechs with some very targeted stock selections.
Published:
Monday's top analyst upgrades, downgrades and initiations include Exxon Mobil, Home Depot, Lululemon Athletica, 3M, Vodafone, Mondelez International and Chevron.
Published:
A new research note from SunTrust Robinson Humphrey mentions four stocks that they think could possibly get swept up in the biotech M&A excitement.
Published:
Here are three biotech stocks that a SunTrust analyst feels could be buyout candidates, in the wake of the Pharmacyclics acquisition.
Published:
In a trend that seems somewhat locked into place, insiders continue to sell stock, though as we have seen most of this year, nobody is rushing to the exits, at least for now.
Published:
Agenus, in conjunction with Incyte, announced a global license for the development and commercialization of Agenus's proprietary Retrocyte Display antibody discovery platform.
Published:
At least five upcoming dates could be big days in December, for better or worse, for individual biotech stocks.
Published: